Global Cardiology Academy

Welcome to Global
Cardiology Academy

Enhance your cardiology practice with CME and
tools focused on heart health management.

Highlights of the Latest Hypertension Guidelines
Highlights of the Latest Hypertension Guidelines
Cardiology
Highlights of the Latest Hypertension Guidelines
- Clyde W. Yancy, MD
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart Matters
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
- Susan Davis
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart Matters
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Cardiology
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
- Ahmad Masri, MD, MS
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Cardiology
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
- Ambarish Pandey, MD
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Cardiology
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
- Jung-Sun Kim, MD, PhD
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Cardiology
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
- Atul Verma, MD
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
Cardiology
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
- Prof. Kausik Ray

Programs

Clinical Perspective on New Therapies in Resistant Hypertension
Clinical Perspective on New Therapies in Resistant Hypertension
Cardiology
Clinical Perspective on New Therapies in Resistant Hypertension
- Clyde W. Yancy, MD
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart Matters
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
- Jun-ichi Abe, MD, PhD
The Fifth Pillar? Closing the Gap in HFrEF
The Fifth Pillar? Closing the Gap in HFrEF
CME/CE
The Fifth Pillar? Closing the Gap in HFrEF
0.50 credits
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Javed Butler, MD
- Stephen J. Greene, MD, FACC, FHFSA
0.50 credits
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Cardiology
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
- Christopher Wong
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Cardiology
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
- Erin Bohula, MD, DPhil
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
Cardiology
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
- Nihar Desai, MD
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
Cardiology
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
- Lawrence Leiter
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Nephrology
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
- Richard E. Pratley, MD

Clinical Practice

Exploring Patient Perspectives on Genetic Testing for ATTR-CM
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
On the Frontlines of ATTR-CM
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
- Shelina Ramnarine, PhD
- Quan Bui, MD
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
Nephrology
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
- prof. Hiddo Heerspink
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
Heart Matters
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
0.50 credits
- prof. Hiddo Heerspink
- Peter Rossing, MD, DMSc
- Paola Fioretto, MD
0.50 credits
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
CME/CE
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
0.25 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Prof. Dr. Francesc Xavier Cos Claramunt
0.25 credits
MinuteCE®
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Leonie Kraft, MD
- Lucio Manenti, MD, PhD
- Emilio Sanchez, MD, PhD
1.00 credit 9 episodes
Managing Genotype-Positive Patients in Hereditary ATTR-CM
Managing Genotype-Positive Patients in Hereditary ATTR-CM
On the Frontlines of ATTR-CM
Managing Genotype-Positive Patients in Hereditary ATTR-CM
- Shelina Ramnarine, PhD
- Naveen L. Pereira, MD
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
CME/CE Broadcast Replay
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
0.50 credits
- Iacopo Olivotto, MD
- Ahmad Masri, MD, MS
- Pablo Garcia-Pavia, MD, PhD
- Fabian Knebel, MD, PhD
- Caroline Coats, MD
0.50 credits

CME

Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
CME/CE
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
0.25 credits
- Scott Solomon, MD
0.25 credits
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Cardiology
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
- Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CE
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
0.50 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Amy Mottl, MD, MPH
- Muthiah Vaduganathan, MD, MPH
0.50 credits
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
MinuteCE®
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits
MinuteCE®
From Risk to Results: Cases in ASCVD Prevention and Treatment
1.00 credit 10 episodes
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 credit 10 episodes
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
MinuteCE®
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
MinuteCE®
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit